Bionomics appoints US-based Chief Business Officer

Company News

Bionomics (ASX:BNO) has appointed Tony Colasin Chief Business Officer.

Bionomics is a South Australian-based company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer.

Mr Colasin will be based in San Diego, California. He will lead the company's corporate development including business development and strategic opportunities.

“We are delighted to welcome Tony to the Bionomics team. His operational experience in our core therapeutic areas – CNS and oncology – as well as his ability to execute on business development activities will be critical as we continue to advance our clinical programs and expand our U.S. presence,” said Deborah Rathjen, Chief Executive Officer and Managing Director of Bionomics.

Mr Colasin brings over two decades experience in senior business development, product commercialisation, and corporate finance roles at major biopharmaceutical companies, contributing to the success of key brands including EPOGEN and CIALIS.

He joins Bionomics from Ironwood Pharmaceuticals, where he served as Vice President of Corporate Development, responsible for strategy and tactical oversight of in-licensing, and mergers and acquisitions.

He was previously Senior Director of Business Development for ICOS Corporation for six years, and before that held positions at Amgen in various marketing, corporate finance and corporate development roles.

Mr Colasin holds a B.S. from the University of Southern California and a M.B.A. from the Anderson School of Management at the University of California, Los Angeles. He also served in the U.S. Marine Corps.

"I am very much looking forward to working with the Bionomics team to grow the company and its strategic footprint in the US and worldwide," said Mr. Colasin. "I see tremendous opportunity for both our CNS and cancer pipelines, especially our lead programs BNC210 for anxiety and depression, and BNC101 targeting cancer stem cells."